Global AI in Clinical Trials Market Forecast: Major Growth Ahead Through 2034#India#Drug_Development#Pune#patient_recruitment#AI_in_Clinical_Trials
Global AI in Clinical Trials Market Forecast: Major Growth Ahead Through 2034
The AI in Clinical Trials Market is expected to expand significantly, reaching USD 7.32 billion by 2034, fueled by advancements in patient recruitment and data analysis.
third-news.com
September 25, 2026 at 10:25 PM
Global AI in Clinical Trials Market Forecast: Major Growth Ahead Through 2034#India#Drug_Development#Pune#patient_recruitment#AI_in_Clinical_Trials
Understanding the Impact of Residual Reagents in Drug Development: A Critical Webinar by Xtalks#None#Drug_Development#Xtalks_Webinar#Impurity_Control
Understanding the Impact of Residual Reagents in Drug Development: A Critical Webinar by Xtalks
Join an upcoming free webinar hosted by Xtalks to understand how residual reagents affect drug safety and efficacy in development processes.
third-news.com
September 21, 2026 at 12:40 PM
Understanding the Impact of Residual Reagents in Drug Development: A Critical Webinar by Xtalks#None#Drug_Development#Xtalks_Webinar#Impurity_Control
Innovative Meeting Announced to Address Drug Development for Idiopathic Hypersomnia#United_States#Drug_Development#Sleep_Consortium#Hypersomnia#West_Palm_Beach
Innovative Meeting Announced to Address Drug Development for Idiopathic Hypersomnia
The Sleep Consortium introduces the Illuminate Hypersomnia Adjunct Scientific Meeting, set to explore solutions for drug development challenges in treating idiopathic hypersomnia.
third-news.com
November 26, 2024 at 3:12 PM
Innovative Meeting Announced to Address Drug Development for Idiopathic Hypersomnia#United_States#Drug_Development#Sleep_Consortium#Hypersomnia#West_Palm_Beach
Veeva Introduces Falcon: Revolutionizing Drug Development with AI Agents#USA#Veeva_Systems#Drug_Development#Pleasanton#Falcon_AI
Veeva Introduces Falcon: Revolutionizing Drug Development with AI Agents
Veeva Systems unveiled Falcon, a groundbreaking AI agent platform aimed at transforming drug development processes for biopharma organizations, streamlining costs.
third-news.com
May 27, 2026 at 3:21 PM
Veeva Introduces Falcon: Revolutionizing Drug Development with AI Agents#USA#Veeva_Systems#Drug_Development#Pleasanton#Falcon_AI
Abbisko Therapeutics Joins Forces with Eli Lilly for Innovative Drug Development#China#Shanghai#Drug_Development#Eli_Lilly#Abbisko_Therapeutics
Abbisko Therapeutics Joins Forces with Eli Lilly for Innovative Drug Development
Abbisko Therapeutics has partnered with Eli Lilly to enhance drug discovery and development across multiple targets, promising innovative treatments.
third-news.com
June 24, 2026 at 1:12 AM
Abbisko Therapeutics Joins Forces with Eli Lilly for Innovative Drug Development#China#Shanghai#Drug_Development#Eli_Lilly#Abbisko_Therapeutics
Veeva Launches Falcon Platform to Revolutionize Drug Development with Agentic Technologies#USA#Veeva_Systems#Drug_Development#Pleasanton#Veeva_Falcon
Veeva Launches Falcon Platform to Revolutionize Drug Development with Agentic Technologies
Veeva Systems unveiled Falcon, an innovative platform to enhance drug development efficiency. It promises reduced costs and faster processes for biopharma companies.
third-news.com
May 27, 2026 at 11:11 AM
Veeva Launches Falcon Platform to Revolutionize Drug Development with Agentic Technologies#USA#Veeva_Systems#Drug_Development#Pleasanton#Veeva_Falcon
Revolutionizing Autoimmune Disease Research: HkeyBio's New Platform Improves Drug Development Efficiency#USA#Boston#Drug_Development#Autoimmune_Diseases#HKeyBio
Revolutionizing Autoimmune Disease Research: HkeyBio's New Platform Improves Drug Development Efficiency
HkeyBio has launched a comprehensive disease model platform focused on autoimmune diseases, enhancing drug R&D through innovative translational research strategies.
third-news.com
June 3, 2026 at 3:12 PM
Revolutionizing Autoimmune Disease Research: HkeyBio's New Platform Improves Drug Development Efficiency#USA#Boston#Drug_Development#Autoimmune_Diseases#HKeyBio
Pediatric Clinical Trials Expected to Reach Nearly $32 Billion by 2033#USA#Austin#Drug_Development#BEYFORTUS#Pediatric_Trials
Pediatric Clinical Trials Expected to Reach Nearly $32 Billion by 2033
The pediatric clinical trials market is projected to grow significantly, reaching $31.77 billion by 2033, with key innovations and regulatory support driving this expansion.
third-news.com
September 15, 2025 at 2:40 PM
Pediatric Clinical Trials Expected to Reach Nearly $32 Billion by 2033#USA#Austin#Drug_Development#BEYFORTUS#Pediatric_Trials
Genedata Launches AI-Native CMC Platform to Revolutionize Drug Development and Manufacturing#Drug_Development#Switzerland#Basel#Genedata#AI-Native_CMC
Genedata Launches AI-Native CMC Platform to Revolutionize Drug Development and Manufacturing
Genedata has unveiled an innovative AI-native CMC platform aimed at expediting drug development, enhancing drug quality, and improving regulatory compliance within biopharma.
third-news.com
May 19, 2026 at 1:37 PM
Genedata Launches AI-Native CMC Platform to Revolutionize Drug Development and Manufacturing#Drug_Development#Switzerland#Basel#Genedata#AI-Native_CMC
Veeva Launches Falcon: A Game-Changer for Pharmaceutical Development Stages#USA#Drug_Development#Life_Sciences#Pleasanton#Veeva_Falcon
Veeva Launches Falcon: A Game-Changer for Pharmaceutical Development Stages
Veeva Systems has unveiled Falcon, a new agency platform designed to streamline critical processes in drug development while ensuring regulatory compliance.
third-news.com
May 28, 2026 at 9:59 PM
Veeva Launches Falcon: A Game-Changer for Pharmaceutical Development Stages#USA#Drug_Development#Life_Sciences#Pleasanton#Veeva_Falcon
GBI Biomanufacturing Unveils SmartScale™ GMP Solutions for Rapid Drug Development#USA#Boston#Drug_Development#GBI_Biomanufacturing#SmartScale™
GBI Biomanufacturing Unveils SmartScale™ GMP Solutions for Rapid Drug Development
GBI Biomanufacturing introduces SmartScale™, a game-changing GMP solution aimed at expediting the clinical trial process for drug developers.
third-news.com
September 17, 2026 at 12:16 PM
GBI Biomanufacturing Unveils SmartScale™ GMP Solutions for Rapid Drug Development#USA#Boston#Drug_Development#GBI_Biomanufacturing#SmartScale™
Revolutionizing Drug Development: Quotient Sciences Launches AI-Designed Clinical Study#United_Kingdom#Drug_Development#Nottingham#AI_in_Pharma#Quotient_Sciences
Revolutionizing Drug Development: Quotient Sciences Launches AI-Designed Clinical Study
Quotient Sciences has initiated a groundbreaking clinical study for an AI-designed drug product, showcasing the potential of artificial intelligence in accelerating medicine development.
third-news.com
May 28, 2026 at 2:16 PM
Revolutionizing Drug Development: Quotient Sciences Launches AI-Designed Clinical Study#United_Kingdom#Drug_Development#Nottingham#AI_in_Pharma#Quotient_Sciences
Xtalks Life Science Podcast Concludes 2025 with In-Depth Insights into Drug Innovations and Future Prospects#Canada#Toronto#Drug_Development#Life_Science#Xtalks
Xtalks Life Science Podcast Concludes 2025 with In-Depth Insights into Drug Innovations and Future Prospects
The Xtalks Life Science Podcast's 2025 finale delves into drug development trends, regulation changes, and innovations, setting the stage for 2026.
third-news.com
December 19, 2025 at 1:37 PM
Xtalks Life Science Podcast Concludes 2025 with In-Depth Insights into Drug Innovations and Future Prospects#Canada#Toronto#Drug_Development#Life_Science#Xtalks
Seven Leading Pharmaceutical Firms Embrace PhaseV's Advanced ML Tools for Drug Development Success#USA#Boston#PhaseV#Machine_Learning#Drug_Development
Seven Leading Pharmaceutical Firms Embrace PhaseV's Advanced ML Tools for Drug Development Success
Seven global pharmaceutical companies are utilizing PhaseV's machine learning technologies to revolutionize drug development processes in various therapeutic areas.
third-news.com
November 25, 2024 at 1:37 PM
Seven Leading Pharmaceutical Firms Embrace PhaseV's Advanced ML Tools for Drug Development Success#USA#Boston#PhaseV#Machine_Learning#Drug_Development
Sanyou Bio's Transformative Journey: A Decade of Innovations in Drug Development#China#Shanghai#Drug_Development#Sanyou_Bio#Antibody_Library
Sanyou Bio's Transformative Journey: A Decade of Innovations in Drug Development
Sanyou Bio has transformed from a startup to a leader in drug development over the past decade, establishing itself as a crucial player in the biopharmaceutical landscape with its Intelligent Super-Trillion Antibody Library.
third-news.com
January 31, 2026 at 8:25 AM
Sanyou Bio's Transformative Journey: A Decade of Innovations in Drug Development#China#Shanghai#Drug_Development#Sanyou_Bio#Antibody_Library
ModernVivo Introduces Marketplace to Expedite Preclinical CRO Selection for Researchers#USA#Seattle#Drug_Development#ModernVivo#CRO_Selection
ModernVivo Introduces Marketplace to Expedite Preclinical CRO Selection for Researchers
ModernVivo has unveiled a revolutionary Marketplace service to streamline the process of connecting preclinical teams with qualified CROs, accelerating drug development timelines.
third-news.com
September 15, 2026 at 1:07 PM
ModernVivo Introduces Marketplace to Expedite Preclinical CRO Selection for Researchers#USA#Seattle#Drug_Development#ModernVivo#CRO_Selection
Angel Bridge Selected as Certified Venture Capital by AMED for Drug Venture Ecosystem Enhancement#Japan#Drug_Development#Chiyoda#Angel_Bridge#AMED
Angel Bridge Selected as Certified Venture Capital by AMED for Drug Venture Ecosystem Enhancement
Angel Bridge has been chosen as a certified venture capital firm by AMED, aiming to enhance the drug venture ecosystem in Japan and support startups with funding.
third-news.com
August 27, 2026 at 5:31 AM
Angel Bridge Selected as Certified Venture Capital by AMED for Drug Venture Ecosystem Enhancement#Japan#Drug_Development#Chiyoda#Angel_Bridge#AMED
Biohaven's Innovative Drug Development Shows Promise in Latest Clinical Trials for Autoimmune Diseases and Epilepsy#USA#Biohaven#New_Haven#Clinical_Trials#Drug_Development
Biohaven's Innovative Drug Development Shows Promise in Latest Clinical Trials for Autoimmune Diseases and Epilepsy
Biohaven Ltd. recently reported significant advancements in its clinical trials, showcasing rapid progress in treating autoimmune diseases like Graves' disease and IgA nephropathy, and offering new hope for epilepsy patients.
third-news.com
August 10, 2026 at 8:04 PM
Biohaven's Innovative Drug Development Shows Promise in Latest Clinical Trials for Autoimmune Diseases and Epilepsy#USA#Biohaven#New_Haven#Clinical_Trials#Drug_Development
Clarivate Enhances Cortellis with Advanced Agentic AI to Boost Drug Development Efficiency#USA#London#Drug_Development#Clarivate#Cortellis
Clarivate Enhances Cortellis with Advanced Agentic AI to Boost Drug Development Efficiency
Clarivate has expanded agentic AI across the Cortellis suite, streamlining drug development processes and enhancing decision-making for life sciences teams.
third-news.com
August 6, 2026 at 8:06 AM
Clarivate Enhances Cortellis with Advanced Agentic AI to Boost Drug Development Efficiency#USA#London#Drug_Development#Clarivate#Cortellis
Trellis Bioscience Secures $9 Million for Advanced Development of Calpurbatug in Fight Against Joint Infections#United_States#Redwood_City#Drug_Development#Trellis_Bioscience#Calpurbatug
Trellis Bioscience Secures $9 Million for Advanced Development of Calpurbatug in Fight Against Joint Infections
Trellis Bioscience announces $9 million funding for clinical development of Calpurbatug, targeting chronic joint infections. Learn more.
third-news.com
July 16, 2026 at 9:36 PM
Trellis Bioscience Secures $9 Million for Advanced Development of Calpurbatug in Fight Against Joint Infections#United_States#Redwood_City#Drug_Development#Trellis_Bioscience#Calpurbatug
HKeyBio Launches Revolutionary HKEY-AI-NAM-Bridge™ 1.0 Enhancing Drug Development Efficiency#USA#Boston#AI_Technology#Drug_Development#HKeyBio
HKeyBio Launches Revolutionary HKEY-AI-NAM-Bridge™ 1.0 Enhancing Drug Development Efficiency
HKeyBio introduces the HKEY-AI-NAM-Bridge™ 1.0, a groundbreaking service that merges AI with preclinical drug development methodologies to foster innovation.
third-news.com
July 13, 2026 at 1:31 PM
HKeyBio Launches Revolutionary HKEY-AI-NAM-Bridge™ 1.0 Enhancing Drug Development Efficiency#USA#Boston#AI_Technology#Drug_Development#HKeyBio
Taiho Innovations Strengthens Co-Creation Foundation with New Clinical Development Initiatives#Japan#Tokyo#Clinical_Trials#Drug_Development#Taiho_Innovations
Taiho Innovations Strengthens Co-Creation Foundation with New Clinical Development Initiatives
Taiho Innovations has announced a new corporate structure and expanded capabilities to enhance its clinical development support for drug innovation.
third-news.com
July 2, 2026 at 4:39 AM
Taiho Innovations Strengthens Co-Creation Foundation with New Clinical Development Initiatives#Japan#Tokyo#Clinical_Trials#Drug_Development#Taiho_Innovations
Significant Growth Expected in Global Oncology-Based In-Vivo CRO Market by 2034#USA#Las_Vegas#oncology#Drug_Development#In-Vivo_CRO
Significant Growth Expected in Global Oncology-Based In-Vivo CRO Market by 2034
The oncology-based in-vivo CRO market is projected to grow at a CAGR of ~8% by 2034, driven by increasing cancer rates and a growing demand for preclinical research services.
third-news.com
July 1, 2026 at 2:48 PM
Significant Growth Expected in Global Oncology-Based In-Vivo CRO Market by 2034#USA#Las_Vegas#oncology#Drug_Development#In-Vivo_CRO
Biosimulation Market Growth Forecast: From $4.27 Billion in 2026 to $9.24 Billion in 2031#USA#Delray_Beach#Drug_Development#Market#Biosimulation
Biosimulation Market Growth Forecast: From $4.27 Billion in 2026 to $9.24 Billion in 2031
The Biosimulation Market is set to expand significantly, projected to reach $9.24 billion by 2031. Explore the factors driving this growth.
third-news.com
June 16, 2026 at 3:37 PM
Biosimulation Market Growth Forecast: From $4.27 Billion in 2026 to $9.24 Billion in 2031#USA#Delray_Beach#Drug_Development#Market#Biosimulation
HkeyBio Introduces Affordable NHP Fast-PoC Program for Biotech Firms#China#Suzhou#Drug_Development#HKeyBio#NHP_Fast-PoC
HkeyBio Introduces Affordable NHP Fast-PoC Program for Biotech Firms
HkeyBio unveils its innovative NHP Fast-PoC program, offering low-cost pharmacological validation data to help biotech companies navigate drug development challenges.
third-news.com
June 10, 2026 at 2:50 PM
HkeyBio Introduces Affordable NHP Fast-PoC Program for Biotech Firms#China#Suzhou#Drug_Development#HKeyBio#NHP_Fast-PoC